PMID: 11334838May 4, 2001Paper

Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia

Cardiovascular Research
Luc M HondeghemFred De Clerck

Abstract

To evaluate whether prolongation of the plateau of the action potential duration, in the absence of instability and triangulation, can reverse the proarrhythmia elicited by a class III antiarrhythmic agent. The effects of almokalant, erythromycin and their combination, on cardiac electrophysiological parameters (action potential duration (APD), instability, triangulation and ectopics) were evaluated in isolated hearts from female albino rabbits. In this study, proarrhythmia was estimated quantitatively by number of ectopic beats. Erythromycin lengthened the APD primarily by a prolongation of the plateau, while having only minor effects upon phase 3 repolarization. The prolongation did not induce much instability, triangulation or reverse use dependence and, as expected, erythromycin did not induce significant proarrhythmia. Almokalant also lengthened APD, but it did not lengthen the plateau; instead, it prolonged phase 3 repolarization. The prolongation markedly triangulated the action potential, elicited much instability and marked reverse use dependence. This combination of effects induced very marked proarrhythmia. When almokalant and erythromycin were combined, their effects upon APD appeared additive: both the plateau and ...Continue Reading

Citations

Jul 1, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Eman Abu-GharbiehFabrizio De Ponti
Dec 5, 2003·Trends in Pharmacological Sciences·Luiz BelardinelliMarc A Vos
Jun 7, 2005·Journal of Pharmacological and Toxicological Methods·H van der LindeD J Gallacher
Aug 7, 2002·European Journal of Pharmacology·András Farkas, Susan J Coker
Jul 23, 2003·European Journal of Pharmacology·András Farkas, Susan J Coker
Apr 5, 2012·Circulation·Andrew J Sauer, Christopher Newton-Cheh
Nov 26, 2009·Canadian Journal of Physiology and Pharmacology·Qiang-Ni LiuFan-Dian Zeng
Jun 7, 2005·Expert Opinion on Drug Safety·Martin Traebert, Berengere Dumotier
Mar 15, 2015·Journal of Molecular and Cellular Cardiology·James N WeissZhilin Qu
Jul 22, 2015·Nature Reviews. Cardiology·Gerrit Frommeyer, Lars Eckardt
Jul 12, 2008·Pharmacology & Therapeutics·Jules C HancoxYi Hong Zhang
Mar 26, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Morten Grunnet
Apr 29, 2003·Journal of Cardiovascular Electrophysiology·Luc M HondeghemFred De Clerck
Jul 10, 2013·Pharmacotherapy·Jaime E GonzalezMori J Krantz
Mar 8, 2005·Trends in Pharmacological Sciences·Michael C Sanguinetti, John S Mitcheson
Jun 3, 2004·Journal of Pharmacological and Toxicological Methods·Jean-Pierre ValentinLuc Hondeghem
Oct 24, 2006·European Journal of Pharmacology·Hua Rong LuDavid J Gallacher
Jun 25, 2005·Journal of Pharmacological and Toxicological Methods·Chris L LawrenceJean-Pierre Valentin
Jun 14, 2005·Journal of Pharmacological and Toxicological Methods·Gayle ProvanSarra K Laycock
Jan 11, 2007·Journal of Cardiovascular Electrophysiology·Donglin GuoGan-Xin Yan
Feb 15, 2007·Expert Opinion on Therapeutic Targets·Harry J Witchel
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
Jun 3, 2014·Journal of Cardiovascular Pharmacology·Szabolcs OroszAndrás Farkas
Apr 23, 2014·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Mats F Nilsson, William S Webster
Jan 31, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Elizabeth M Cherry, Flavio H Fenton
May 5, 2017·Clinical Medicine Insights. Cardiology·Andrew G Edwards, William E Louch
Sep 23, 2003·Circulation Research·Michael C Sanguinetti, Paul B Bennett
Jun 13, 2012·The Journal of Toxicological Sciences·Anusak KijtawornratRobert L Hamlin
May 9, 2012·Journal of Cardiovascular Pharmacology·Tamer H SaidDavid S Rosenbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.